Target Enrichment Solution now Available for Ion Proton Next-Generation Sequencing Systems

Agilent Technologies Inc have introduced a new SureSelect target enrichment solution that allows Ion Proton users to realise the full power of their next-generation sequencers with the industry’s leading human exome and custom DNA target enrichment solutions. SureSelect target enrichment is now available for all major sequencing platforms, enabling researchers to achieve the highest-performance target enrichment results with a variety of sequencers.

“The adoption of desktop sequencers has increased dramatically over the past few years, enabling next-generation sequencing to expand further into clinical research,” said Jacob Thaysen, Agilent’s Vice President of the Genomic Solutions Division. “We are happy to provide Ion Proton researchers access to one of the industry’s leading target enrichment solutions.”

Already used extensively with high-throughput and desktop sequencers, SureSelect solutions yield high sensitivity and specificity with a fast, easy workflow, generating sequencer-ready samples in only 1.5 days. A number of other distinctive features include highly uniform sequencing coverage, with more than 99% SNP concordance rates. SureSelect’s flexibility also enables researchers to easily create custom panels specific to their targets of interest with SureDesign, Agilent’s user-friendly online design software.

SureSelect Human All Exon V5 is the most widely used human exome kit and is now available for Ion Proton researchers using the SureSelect TE Reagent Kit for Ion Proton. Agilent provides high-performance flexibility and a complete solution for next-generation target enrichment sequencing, including target enrichment reagents, automation, QC and analysis.